Painful Diabetic Peripheral Neuropathy: Practical Guidance and Challenges for Clinical Management
Frank G Preston,David R Riley,Shazli Azmi,Uazman Alam
DOI: https://doi.org/10.2147/DMSO.S370050
2023-06-02
Abstract:Frank G Preston, 1 David R Riley, 1 Shazli Azmi, 2 Uazman Alam 1, 3 1 Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences and the Pain Research Institute, University of Liverpool, Liverpool, UK; 2 Institute of Cardiovascular Science, University of Manchester and Manchester Diabetes Centre, Manchester Foundation Trust, Manchester, UK; 3 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool University Hospital NHS Foundation Trust, Liverpool, UK Correspondence: Uazman Alam, Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool, L9 7AL, UK, Tel +44 0151 529 5918, Fax +44 0151 529 5888, Email Painful diabetic peripheral neuropathy (PDPN) is present in nearly a quarter of people with diabetes. It is estimated to affect over 100 million people worldwide. PDPN is associated with impaired daily functioning, depression, sleep disturbance, financial instability, and a decreased quality of life. Despite its high prevalence and significant health burden, it remains an underdiagnosed and undertreated condition. PDPN is a complex pain phenomenon with the experience of pain associated with and exacerbated by poor sleep and low mood. A holistic approach to patient-centred care alongside the pharmacological therapy is required to maximise benefit. A key treatment challenge is managing patient expectation, as a good outcome from treatment is defined as a reduction in pain of 30– 50%, with a complete pain-free outcome being rare. The future for the treatment of PDPN holds promise, despite a 20-year void in the licensing of new analgesic agents for neuropathic pain. There are over 50 new molecular entities reaching clinical development and several demonstrating benefit in early-stage clinical trials. We review the current approaches to its diagnosis, the tools, and questionnaires available to clinicians, international guidance on PDPN management, and existing pharmacological and non-pharmacological treatment options. We synthesise evidence and the guidance from the American Association of Clinical Endocrinology, American Academy of Neurology, American Diabetes Association, Diabetes Canada, German Diabetes Association, and the International Diabetes Federation into a practical guide to the treatment of PDPN and highlight the need for future research into mechanistic-based treatments in order to prioritise the development of personalised medicine. Keywords: diabetic peripheral neuropathy, painful diabetic peripheral neuropathy, diabetes complications, pharmacotherapy In 2021, the global prevalence of diabetes mellitus was estimated at 537 million and is expected to rise to 783 million by 2045. 1 Diabetic neuropathy affects up to 50% of patients with diabetes 2,3 and refers to a heterogenous group of disorders which affect the nervous system leading to a range of clinical presentations. 4 The most prevalent form is diabetic peripheral neuropathy (DPN), a symmetrical, length-dependent sensorimotor polyneuropathy. 5 DPN typically presents in a "stocking and glove" distribution, beginning distally and moving proximally with disease progression, with lower-limb long axons being most vulnerable to damage. 4 DPN may lead to neuropathic pain 6 and is the largest initiating risk factor for foot ulceration and amputation. 7 Painful DPN (PDPN) affects ~20–24% of patients with diabetes and leads to impaired daily functioning, depression, sleep disturbance, financial instability, 8 and decreased quality of life (QoL). 9 PDPN is characterised as burning, tingling, and electric shock-like sensation which may be accompanied by negative symptoms (numbness) or positive symptoms (paraesthesia, allodynia [pain sensitisation following normally non-painful stimulation] and hyperalgesia [abnormally increased sensitivity to pain]). 4 PDPN is underdiagnosed and undertreated by healthcare professionals. 10,11 Several challenges exist in the management of PDPN including lack of timely diagnosis, PDPN refractory to anti-neuropathic therapy, an absence of mechanistic-based treatment in routine clinical practice, and inconsistencies between international guidelines. In this narrative review, we discuss practical guidance and challenges for the clinical management of PDPN. The current screening for DPN relies on a combination of history and clinical neurological examination. According to the American Diabetes Association (ADA), individuals diagnosed with type 2 diabetes should have screening at the time of diagnosis, while individuals with type 1 diabetes should -Abstract Truncated-
endocrinology & metabolism